BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tebbens RJ, Pallansch MA, Alexander JP, Thompson KM. Optimal vaccine stockpile design for an eradicated disease: application to polio. Vaccine 2010;28:4312-27. [PMID: 20430122 DOI: 10.1016/j.vaccine.2010.04.001] [Cited by in Crossref: 42] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Linkins J, Sutter RW, Aylward RB, Thompson KM. Economic analysis of the global polio eradication initiative. Vaccine 2010;29:334-43. [DOI: 10.1016/j.vaccine.2010.10.026] [Cited by in Crossref: 99] [Cited by in F6Publishing: 78] [Article Influence: 9.0] [Reference Citation Analysis]
2 Thompson KM. Modeling poliovirus risks and the legacy of polio eradication. Risk Anal 2013;33:505-15. [PMID: 23550939 DOI: 10.1111/risa.12030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
3 Rahmandad H, Hu K, Tebbens RJD, Thompson KM. Development of an individual-based model for polioviruses: implications of the selection of network type and outcome metrics. Epidemiol Infect 2011;139:836-48. [DOI: 10.1017/s0950268810001676] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
4 Guo J, Bolivar-Wagers S, Srinivas N, Holubar M, Maldonado Y. Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication. Vaccine 2015;33:1235-42. [PMID: 25600519 DOI: 10.1016/j.vaccine.2015.01.018] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
5 Kalkowska DA, Voorman A, Pallansch MA, Wassilak SGF, Cochi SL, Badizadegan K, Thompson KM. The impact of disruptions caused by the COVID-19 pandemic on global polio eradication. Vaccine 2021:S0264-410X(21)00473-4. [PMID: 33962838 DOI: 10.1016/j.vaccine.2021.04.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
6 Duintjer Tebbens RJ, Pallansch MA, Wassilak SG, Cochi SL, Thompson KM. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. BMC Infect Dis 2016;16:137. [PMID: 27009272 DOI: 10.1186/s12879-016-1465-7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
7 Minor PD. The polio-eradication programme and issues of the end game. J Gen Virol 2012;93:457-74. [PMID: 22128250 DOI: 10.1099/vir.0.036988-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
8 Thompson KM, Duintjer Tebbens RJ. Framework for Optimal Global Vaccine Stockpile Design for Vaccine-Preventable Diseases: Application to Measles and Cholera Vaccines as Contrasting Examples. Risk Anal 2016;36:1487-509. [PMID: 25109229 DOI: 10.1111/risa.12265] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
9 Duintjer Tebbens RJ, Thompson KM. Poliovirus vaccination during the endgame: insights from integrated modeling. Expert Review of Vaccines 2017;16:577-86. [DOI: 10.1080/14760584.2017.1322514] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
10 Kraan H, van Herpen P, Kersten G, Amorij JP. Development of thermostable lyophilized inactivated polio vaccine. Pharm Res 2014;31:2618-29. [PMID: 24760448 DOI: 10.1007/s11095-014-1359-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
11 Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Wassilak SG, Cochi SL. Polio Eradicators Use Integrated Analytical Models to Make Better Decisions. Interfaces 2015;45:5-25. [DOI: 10.1287/inte.2014.0769] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
12 Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SG, Cochi SL, Kim JH, Thompson KM. Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs. Risk Anal 2013;33:606-46. [PMID: 23550968 DOI: 10.1111/risa.12031] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 7.5] [Reference Citation Analysis]
13 Kalkowska DA, Pallansch MA, Cochi SL, Kovacs SD, Wassilak SGF, Thompson KM. Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart. Risk Anal 2021;41:320-8. [PMID: 32632925 DOI: 10.1111/risa.13555] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
14 Decouttere C, De Boeck K, Vandaele N. Advancing sustainable development goals through immunization: a literature review. Global Health 2021;17:95. [PMID: 34446050 DOI: 10.1186/s12992-021-00745-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Thompson KM, Kalkowska DA. Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame. Risk Anal 2021;41:229-47. [PMID: 32339327 DOI: 10.1111/risa.13484] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
16 Thompson KM, Wallace GS, Tebbens RJ, Smith PJ, Barskey AE, Pallansch MA, Gallagher KM, Alexander JP, Armstrong GL, Cochi SL, Wassilak SG. Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response. Public Health Rep 2012;127:23-37. [PMID: 22298920 DOI: 10.1177/003335491212700104] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
17 Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SG, Kim JH, Cochi SL. Preeradication vaccine policy options for poliovirus infection and disease control. Risk Anal 2013;33:516-43. [PMID: 23461599 DOI: 10.1111/risa.12019] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 5.5] [Reference Citation Analysis]
18 Kalkowska DA, Pallansch MA, Wassilak SGF, Cochi SL, Thompson KM. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response. Vaccine 2021:S0264-410X(21)00543-0. [PMID: 33994237 DOI: 10.1016/j.vaccine.2021.04.061] [Reference Citation Analysis]
19 Dasaklis TK, Pappis CP, Rachaniotis NP. Epidemics control and logistics operations: A review. International Journal of Production Economics 2012;139:393-410. [DOI: 10.1016/j.ijpe.2012.05.023] [Cited by in Crossref: 104] [Cited by in F6Publishing: 14] [Article Influence: 11.6] [Reference Citation Analysis]
20 Shulman LM. Polio and Its Epidemiology. In: Kanki P, Grimes DJ, editors. Infectious Diseases. New York: Springer; 2013. pp. 237-308. [DOI: 10.1007/978-1-4614-5719-0_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
21 Kisjes KH, Duintjer Tebbens RJ, Wallace GS, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM. Individual-based modeling of potential poliovirus transmission in connected religious communities in North America with low uptake of vaccination. J Infect Dis 2014;210 Suppl 1:S424-33. [PMID: 25316864 DOI: 10.1093/infdis/jit843] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
22 Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM. An economic analysis of poliovirus risk management policy options for 2013-2052. BMC Infect Dis 2015;15:389. [PMID: 26404632 DOI: 10.1186/s12879-015-1112-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 7.2] [Reference Citation Analysis]
23 Tebbens RJD, Thompson KM. Using integrated modeling to support the global eradication of vaccine-preventable diseases. Syst Dyn Rev 2018;34:78-120. [PMID: 34552305 DOI: 10.1002/sdr.1589] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
24 Thompson KM, Kalkowska DA. Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication. Expert Rev Vaccines 2020;19:661-86. [PMID: 32741232 DOI: 10.1080/14760584.2020.1791093] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]